Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 1:01 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 289–312 of 1,658 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Schizophrenia; Psychosis Clear all
Completed Phase 2 Interventional Results available

A Study to Evaluate Multiple Oral Doses of Luvadaxistat in Adults With Schizophrenia

NCT03359785
View directory record Official record
Conditions
Schizophrenia
Interventions
Luvadaxistat, Matching Placebo
Drug
Lead sponsor
Neurocrine Biosciences
Industry
Eligibility
18 Years to 60 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Gaithersburg, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 28, 2024 · Synced Oct 14, 2026, 1:01 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Imaging of Brain Receptors in Healthy Volunteers and in Patients With Schizophrenia

NCT00061789
View directory record Official record
Conditions
Schizophrenia
Interventions
SPECT Imaging of Nicotinic Acetylcholine Receptors in Brain
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
Not listed
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2004
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 14, 2026, 1:01 PM EDT
Completed Phase 4 Interventional Results available

High Dose Risperidone Consta for Patients With Schizophrenia With Poor Response to Risperidone

NCT00539071
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
long-acting injectable risperidone, long acting injectable risperidone, Conventional Dose Group, long acting injectable risperidone, High Dose Group
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 65 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 1, 2025 · Synced Oct 14, 2026, 1:01 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

The Effects of Nicotine on Cognition in Schizophrenia

NCT00383747
View directory record Official record
Conditions
Schizophrenia
Interventions
Transdermal Nicotine Patch
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 60 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2009
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 28, 2017 · Synced Oct 14, 2026, 1:01 PM EDT
Withdrawn No phase listed Observational Accepts healthy volunteers

Nicotinic Receptor Density in Smoking and Nonsmoking Schizophrenics

NCT01246128
View directory record Official record
Conditions
Schizophrenia
Interventions
Not listed
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 50 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
2
States / cities
Baltimore, Maryland • Catonsville, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 14, 2026, 1:01 PM EDT
Completed Phase 2 Interventional

Receptor Occupancy of ITI-007 Using Positron Emission Tomography (PET) in Patients With Stable Schizophrenia

NCT02288845
View directory record Official record
Conditions
Schizophrenia
Interventions
ITI-007
Drug
Lead sponsor
Intra-Cellular Therapies, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 10, 2017 · Synced Oct 14, 2026, 1:01 PM EDT
Terminated Not applicable Interventional Results available

Bilateral Repetitive Transcranial Magnetic Stimulation for Auditory Hallucinations Results

NCT04548622
View directory record Official record
Conditions
Schizophrenia
Interventions
Magstim Rapid 2 system triggering Magstim Super Rapid system
Device
Lead sponsor
Yale University
Other
Eligibility
18 Years to 55 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 30, 2020 · Synced Oct 14, 2026, 1:01 PM EDT
Completed Not applicable Interventional Results available

An Integrated Program for the Treatment of First Episode of Psychosis

NCT01321177
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder, Brief Psychotic Disorder, Psychotic Disorder NOS
Interventions
Integrated Treatment, Community Care
Behavioral
Lead sponsor
Northwell Health
Other
Eligibility
15 Years to 40 Years
Enrollment
404 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
33
States / cities
San Fernando, California • Santa Clarita, California • Denver, Colorado + 30 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2021 · Synced Oct 14, 2026, 1:01 PM EDT
Completed No phase listed Observational Results available

Optimizing Cognitive Remediation

NCT04395157
View directory record Official record
Conditions
Schizophrenia, Stress Disorders, Post-Traumatic, Generalized Anxiety Disorder, Mood Disorders
Interventions
Not listed
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Feb 25, 2026 · Synced Oct 14, 2026, 1:01 PM EDT
Completed Not applicable Interventional Results available

Effectiveness of a Mobile Texting Intervention for People With Serious Mental Illness

NCT03062267
View directory record Official record
Conditions
Schizoaffective Disorder, Schizophrenia, Bipolar Disorder, Major Depressive Disorder
Interventions
Mobile Interventionist
Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 99 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
2
States / cities
Chicago, Illinois • Spokane, Washington
Source: ClinicalTrials.gov public record
Updated Nov 9, 2020 · Synced Oct 14, 2026, 1:01 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Neural Oscillations as Genetic and Functional Biomarkers in Normal and Disease States

NCT01425671
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder
Interventions
Not listed
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
14 Years to 62 Years
Enrollment
800 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2024
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 26, 2024 · Synced Oct 14, 2026, 1:01 PM EDT
Not listed Phase 4 Interventional

Huperzine-A to Help With Mental Problems and the Inability to Care for Onself in Patients With Schizophrenia

NCT01012830
View directory record Official record
Conditions
Schizophrenia, Dementia
Interventions
Huperzine A
Drug
Lead sponsor
VA Nebraska Western Iowa Health Care System
Federal
Eligibility
19 Years to 59 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Nov 13, 2009 · Synced Oct 14, 2026, 1:01 PM EDT
Completed Phase 4 Interventional Results available

Reducing Weight Gain and Improving Metabolic Function in Children Being Treated With Antipsychotics

NCT00806234
View directory record Official record
Conditions
Psychotic Disorders
Interventions
Aripiprazole or Perphenazine, Metformin, Olanzapine, quetiapine, risperidone, ziprasidone, aripiprazole, asenapine, iloperidone, lurasidone, paliperidone, or olanzapine/fluoxetine
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
8 Years to 19 Years
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
4
States / cities
Baltimore, Maryland • Glen Oaks, New York • Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 25, 2017 · Synced Oct 14, 2026, 1:01 PM EDT
Recruiting Phase 3 Interventional

NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With Schizophrenia

NCT07114874
View directory record Official record
Conditions
Schizophrenia
Interventions
NBI-1117568
Drug
Lead sponsor
Neurocrine Biosciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
50
States / cities
Bryant, Arkansas • Little Rock, Arkansas • Cerritos, California + 43 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 14, 2026, 1:01 PM EDT
Active, not recruiting Not applicable Interventional

Prebiotic Treatment in People With Schizophrenia

NCT05527210
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Prebiotic, Placebo Prebiotic
Dietary Supplement
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 60 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Catonsville, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 24, 2026 · Synced Oct 14, 2026, 1:01 PM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

NEURO-COGS: Neurometabolic Mechanisms of Cognitive Training in Schizophrenia

NCT07788755
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Cognitive Impairment, Visual Impairment
Interventions
Perceptual Discrimination Training, Cognitive Control Training
Device
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 79 Years
Enrollment
168 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2031
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 14, 2026, 1:01 PM EDT
Completed Phase 1 Interventional

A Study of ALKS 9072 in Subjects With Chronic Stable Schizophrenia

NCT01493726
View directory record Official record
Conditions
Schizophrenia
Interventions
ALKS 9072, Low dose, ALKS 9072, Med dose, ALKS 9072, High dose, Placebo
Drug
Lead sponsor
Alkermes, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
6
States / cities
Atlanta, Georgia • Hoffman Estates, Illinois • St Louis, Missouri + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 29, 2018 · Synced Oct 14, 2026, 1:01 PM EDT
Completed Phase 4 Interventional Results available

Comparison of Antipsychotics for Metabolic Problems in Schizophrenia or Schizoaffective Disorder

NCT00423878
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Risperidone, Olanzapine, Quetiapine, Aripiprazole
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 65 Years
Enrollment
215 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
28
States / cities
Colton, California • Palo Alto, California • New Haven, Connecticut + 25 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Oct 14, 2026, 1:01 PM EDT
Recruiting Not applicable Interventional

FAmily Engagement Strategy for Coordinated Specialty Care

NCT06945055
View directory record Official record
Conditions
Family Members, Implementation
Interventions
FAMES, Control
Behavioral
Lead sponsor
Washington State University
Other
Eligibility
18 Years and older
Enrollment
900 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
4
States / cities
Bend, Oregon • Pasco, Washington • Tacoma, Washington + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2026 · Synced Oct 14, 2026, 1:01 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Imaging Synapses With [11C] UCB-J in the Human Brain

NCT04038840
View directory record Official record
Conditions
Schizophrenia
Interventions
[11C]UCB-J radiotracer, PET-MR
Drug · Device
Lead sponsor
Davidzon, Guido, M.D.
Other
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2025
U.S. locations
2
States / cities
Palo Alto, California • Stanford, California
Source: ClinicalTrials.gov public record
Updated Dec 16, 2024 · Synced Oct 14, 2026, 1:01 PM EDT
Completed Phase 1 Interventional

First in Man Study of Safety, Tolerability and PK Profile of RBP-7000

NCT02765555
View directory record Official record
Conditions
Schizophrenia
Interventions
RBP-7000
Drug
Lead sponsor
Indivior Inc.
Industry
Eligibility
18 Years to 42 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
Willingboro, New Jersey
Source: ClinicalTrials.gov public record
Updated May 6, 2016 · Synced Oct 14, 2026, 1:01 PM EDT
Completed Phase 1 Interventional

Study Assessing the Safety, Tolerability, and Pharmacokinetics of SEP-363856 in Male and Female Subjects With Schizophrenia

NCT01994473
View directory record Official record
Conditions
Schizophrenia
Interventions
SEP-363856, Placebo, SEP-363856 Open Label
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
2
States / cities
Glendale, California • Long Beach, California
Source: ClinicalTrials.gov public record
Updated Jun 26, 2024 · Synced Oct 14, 2026, 1:01 PM EDT
Not listed Not applicable Interventional

Evaluation of Programs of Coordinated Care and Disease Management

NCT00627029
View directory record Official record
Conditions
Congestive Heart Failure, Diabetes, Coronary Artery Disease, Chronic Obstructive Pulmonary Disease, Cancer, Cerebrovascular Disease, Alzheimer's Disease, Psychotic Disorder, Major Depression
Interventions
Care Coordination
Behavioral
Lead sponsor
Mathematica Policy Research, Inc.
Other
Eligibility
Not listed
Enrollment
18,277 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2016
U.S. locations
15
States / cities
Phoenix, Arizona • Washington D.C., District of Columbia • Sunrise, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2015 · Synced Oct 14, 2026, 1:01 PM EDT
Terminated Phase 4 Interventional Results available

Aripiprazole Lauroxil for Preventing Psychotic Relapse After an Initial Schizophrenia Episode

NCT04203056
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Depressive Type, Schizophreniform Disorder
Interventions
Aripiprazole Lauroxil, ARI-ORAL, AL-NCD
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 45 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 28, 2023 · Synced Oct 14, 2026, 1:01 PM EDT